Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin

Ming Han Tsai, Yhu Chering Huang, Meng Hsiu Yen, Chung Chen Li, Cheng Hsun Chiu, Pen Yi Lin, Tzou Yien Lin, Luan Yin Chang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.

Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalJournal of Pediatrics
Volume148
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Mucocutaneous Lymph Node Syndrome
Intravenous Immunoglobulins
Propiolactone
Aneurysm
Coronary Vessels
Retreatment
Passive Immunization
Digestion
Fever
Myocardial Infarction
Physicians
Enzymes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Tsai, M. H., Huang, Y. C., Yen, M. H., Li, C. C., Chiu, C. H., Lin, P. Y., ... Chang, L. Y. (2006). Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin. Journal of Pediatrics, 148(1), 38-43. https://doi.org/10.1016/j.jpeds.2005.08.024

Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin. / Tsai, Ming Han; Huang, Yhu Chering; Yen, Meng Hsiu; Li, Chung Chen; Chiu, Cheng Hsun; Lin, Pen Yi; Lin, Tzou Yien; Chang, Luan Yin.

In: Journal of Pediatrics, Vol. 148, No. 1, 01.2006, p. 38-43.

Research output: Contribution to journalArticle

Tsai, Ming Han ; Huang, Yhu Chering ; Yen, Meng Hsiu ; Li, Chung Chen ; Chiu, Cheng Hsun ; Lin, Pen Yi ; Lin, Tzou Yien ; Chang, Luan Yin. / Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin. In: Journal of Pediatrics. 2006 ; Vol. 148, No. 1. pp. 38-43.
@article{c590500dc2404827a982c37859c8cb12,
title = "Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin",
abstract = "Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6{\%}) were nonresponsive, 17 (3.9{\%}) had CAA at convalescence, and 3 (0.7{\%}) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10{\%}, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13{\%}, 12/93, P = .001); giant aneurysm occurred in 3/93 (3{\%}) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.",
author = "Tsai, {Ming Han} and Huang, {Yhu Chering} and Yen, {Meng Hsiu} and Li, {Chung Chen} and Chiu, {Cheng Hsun} and Lin, {Pen Yi} and Lin, {Tzou Yien} and Chang, {Luan Yin}",
year = "2006",
month = "1",
doi = "10.1016/j.jpeds.2005.08.024",
language = "English",
volume = "148",
pages = "38--43",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin

AU - Tsai, Ming Han

AU - Huang, Yhu Chering

AU - Yen, Meng Hsiu

AU - Li, Chung Chen

AU - Chiu, Cheng Hsun

AU - Lin, Pen Yi

AU - Lin, Tzou Yien

AU - Chang, Luan Yin

PY - 2006/1

Y1 - 2006/1

N2 - Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.

AB - Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.

UR - http://www.scopus.com/inward/record.url?scp=30744441907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744441907&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2005.08.024

DO - 10.1016/j.jpeds.2005.08.024

M3 - Article

VL - 148

SP - 38

EP - 43

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -